For prognostic and treatment response prediction, physicians could implement the shortened list of molecular markers, mainly DNA sequence alterations in IDH1/2 affecting temozolomide response, EGFR amplification or truncation affecting the use of anti-EGFR therapy in glioma, and p-TERT mutations conferring a poor glioma prognosis (Killela et al., 2014). The gene discussed is EGFR; the disease is central nervous system cancer.